Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070265 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00070265: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00070265 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070265, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as capecitabine and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine and oxaliplatin before surgery may shrink the tumor so that it can be removed. Giving capecitabine and oxaliplatin after surgery may kill any remaining tumor cells. This phase II trial is studying how well capecitabine and oxaliplatin work when given before and after surgery in treating patients with resectable liver metastases that is secondary to colorectal cancer
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- PROCEDURE therapeutic conventional surgery
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070265
The ClinicalTrials.gov registry entry for NCT00070265 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00070265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070265 about?
NCT00070265 is a clinical study titled "Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer". Drugs used in chemotherapy, such as capecitabine and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine and oxaliplatin before surgery may shrink the tumor so that it can be removed. Giving capecitabine and oxaliplatin after surgery may...
What is the current status of trial NCT00070265?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00070265?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), therapeutic conventional surgery (PROCEDURE), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00070265?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.